Last Week Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Ratings

May 3, 2018 - By Daniel Cummings

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 1.25. That’s change of 0.44, from 2017Q3’s 1.69. 21 investors sold all, 86 reduced holdings as Ligand Pharmaceuticals Incorporated ratio dropped. 103 grew positions while 31 funds acquired positions. Funds hold 22.68 million shares thus 0.37% less from 2017Q3’s 22.76 million shares.
Bartlett & Ltd Liability Company owns 33 shs. M&T Bancshares Corp accumulated 1,947 shs. 147 are held by Brown Brothers Harriman &. Campbell Newman Asset Mngmt Inc reported 3,495 shs. Knott David M stated it has 762,944 shs or 41.55% of all its holdings. Quantitative Investment Management Llc reported 20,600 shs or 0.04% of all its holdings. Ashford Management holds 127,987 shs or 2.73% of its capital. First Republic Invest Mgmt Inc invested in 0.01% or 5,756 shs. Peak6 Invs Ltd Partnership reported 0.01% stake. Osterweis Capital has invested 0.34% of its capital in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Comerica Bancorp accumulated 29,400 shs. 225,967 are owned by Dimensional Fund Advsrs Lp. Financial Bank Of Montreal Can accumulated 9,922 shs. State Of Alaska Department Of Revenue holds 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) or 4,207 shs. Millennium Ltd Liability Corporation, New York-based fund reported 3,456 shs.

Ligand Pharmaceuticals Incorporated had 12 insider sales and 0 insider buys since December 20, 2017. This’s net activity of $16.28 million. On Wednesday, January 10 KOZARICH JOHN W had sold 2,500 shs worth $362,500. HIGGINS JOHN L sold $4.32M worth of stock. $2.62 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was sold by Davis Todd C. LAMATTINA JOHN L sold $536,604 worth of stock or 3,335 shs. $1.32M worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was sold by Aryeh Jason on Thursday, March 8. FOEHR MATTHEW W had sold 5,444 shs worth $832,824.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Ratings Coverage

In total 5 analysts cover Ligand Pharmaceuticals (NASDAQ:LGND). “Buy” rating has 4, “Sell” are 1, while 0 are “Hold”. 80% are bullish. 10 are the (NASDAQ:LGND)’s analyst reports since November 9, 2017 according to StockzIntelligence Inc. On Wednesday, November 15 the stock has “Buy” rating by Craig Hallum. On Thursday, February 22 the company was maintained by Stephens. On Wednesday, March 7 the stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has “Buy” rating given by H.C. Wainwright. On Thursday, November 9 the stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) earned “Buy” rating by H.C. Wainwright. On Monday, November 13 Roth Capital maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) with “Buy” rating. On Monday, November 20 Deutsche Bank downgraded Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to “Sell” rating. On Monday, February 26 the firm has “Buy” rating given by Roth Capital. On Wednesday, March 7 the stock has “Buy” rating by Craig Hallum. On Wednesday, January 24 the rating was maintained by H.C. Wainwright with “Buy”. On Thursday, February 22 the stock has “Buy” rating by Craig Hallum. Listed here are Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PTs and latest ratings.

07/03/2018 Broker: Craig Hallum Rating: Buy New Target: $200.0 Maintain
07/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $170 New Target: $182 Maintain
26/02/2018 Broker: Roth Capital Rating: Buy New Target: $171.0 Maintain
22/02/2018 Broker: Craig Hallum Rating: Buy New Target: $190.0 Maintain
22/02/2018 Broker: Stephens Rating: Buy New Target: $162.0 Maintain
24/01/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $159 New Target: $170 Maintain
20/11/2017 Broker: Deutsche Bank Old Rating: Hold New Rating: Sell Old Target: $104 Downgrade
15/11/2017 Broker: Craig Hallum Rating: Buy New Target: $170.0 Maintain
13/11/2017 Broker: Roth Capital Rating: Buy New Target: $158.0 Maintain
09/11/2017 Broker: H.C. Wainwright Rating: Buy Old Target: $157 New Target: $159 Maintain

The stock decreased 1.28% or $2.01 during the last trading session, hitting $154.95.Ligand Pharmaceuticals Incorporated has volume of 143,672 shares. Since May 3, 2017 LGND has risen 53.11% and is uptrending. LGND outperformed by 41.56% the S&P 500.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.The firm is valued at $3.29 billion. The Company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer.The P/E ratio is 292.36. The companyÂ’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: